Fig. 1: MUC1 is upregulated in HR+/HER2− BCs and regulates ER-driven gene transcriptomes. | npj Breast Cancer

Fig. 1: MUC1 is upregulated in HR+/HER2− BCs and regulates ER-driven gene transcriptomes.

From: MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment

Fig. 1: MUC1 is upregulated in HR+/HER2− BCs and regulates ER-driven gene transcriptomes.

a and b Analysis of the TCGA BRCA dataset for MUC1 expression in HR+/HER2− BCs vs normal breast tissue (a) and HR+/HER2− vs. ER−/HER2− BCs (b). c MCF-7 and T47D cell membrane (MEM), cytosolic (CYTO) and nucleoplasm (NP) were immunoblotted with antibodies against the indicated proteins. d Chromatin from MCF-7 and T47D cells was immunoblotted with antibodies against the indicated proteins. e Lysates from MCF-7/tet-MUC1shRNA and T47D/tet-shMUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. f and g. GSEA of RNA-seq data from MCF-7 cells (f) and T47D cells (g) with MUC1-C silencing using the HALLMARK ESTROGEN RESPONSE EARLY (upper panels) and HALLMARK ESTROGEN RESPONSE LATE (lower panels) gene signatures. h Common downregulated ERGs and LRGs in MCF-7 and T47D cells with MUC1-C silencing. i and j MCF-7/tet-MUC1shRNA (i) and T47D/tet-MUC1shRNA (j) cells treated with vehicle or DOX for 7 days were analyzed for MUC1-C, TFF1, MYB and BCL2 transcripts by qRT-PCR using primers listed in Supplemental Table S2. The results (mean ± SD of 4 determinations) are expressed as relative levels compared to that obtained for vehicle-treated cells (assigned a value of 1).

Back to article page